Stratification of the Gut Microbiota Composition Landscape across the Alzheimer’s Disease Continuum in a Turkish Cohort Original paper
-
Dr. Umar
Read MoreClinical Pharmacist and Clinical Pharmacy Master’s candidate focused on antibiotic stewardship, AI-driven pharmacy practice, and research that strengthens safe and effective medication use. Experience spans digital health research with Bloomsbury Health (London), pharmacovigilance in patient support programs, and behavioral approaches to mental health care. Published work includes studies on antibiotic use and awareness, AI applications in medicine, postpartum depression management, and patient safety reporting. Developer of an AI-based clinical decision support system designed to enhance antimicrobial stewardship and optimize therapeutic outcomes.
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.
What was studied?
This study examined gut microbiota stratification in Alzheimer’s disease, using 16S rRNA sequencing to characterize microbial community structures across the Alzheimer’s disease (AD) continuum. The goal was to determine whether distinct microbiota subtypes exist in individuals with mild cognitive impairment (MCI) and AD compared with nondemented controls. The investigators applied multiple analytic approaches—including differential abundance testing, beta-diversity metrics, machine learning, Dirichlet multinomial mixtures, latent Dirichlet allocation, and topological data analysis—to identify reproducible ecological clusters. Across methods, two dominant microbiome configurations repeatedly emerged: Prevotella-dominant and Bacteroides-dominant communities. The study also explored how these microbial structures relate to disease severity, cognitive measures (MMSE and CDR), and key taxa that may serve as microbiome-based biomarkers.
Who was studied?
The cohort consisted of 125 Turkish adults: 47 with AD, 27 with amnestic MCI, and 51 nondemented controls, many of whom were spouses sharing similar dietary patterns. Participants were recruited from two university medical centers. Stool samples were collected, and clinical characterization included cognitive testing, education level, demographic information, medication profiles, and cerebrospinal fluid biomarkers for a subset of AD patients. This well-defined clinical stratification allowed the investigators to evaluate how microbiome composition maps onto stages of cognitive impairment while adjusting for confounders such as age, sex, and education.
Most important findings
Across all analytic strategies, the gut microbiota displayed robust stratification, driven primarily by Prevotella and Bacteroides. AD samples showed higher Proteobacteria (notably Escherichia/Shigella) and lower SCFA-producers such as Faecalibacterium. A Bacteroides-enriched “Bact2” enterotype—previously linked to inflammatory states—appeared prominently in a subset of AD participants.
The table below highlights the major microbial patterns consistently identified:
| Microbial Feature | Association Across AD Continuum | Notes |
|---|---|---|
| Prevotella_9 | Higher in controls | Aligns with healthier cognitive profile; strain variability may matter |
| Bacteroides | Elevated in AD, especially Bact2 subtype | Linked to systemic inflammation |
| Escherichia/Shigella | Enriched in AD | Opportunistic/pathobiont signature |
| Faecalibacterium | Reduced in AD | Key SCFA producer; depletion signals dysbiosis |
| Ruminococcaceae (unclassified) | Distinct associations with MCI and AD | Contributes to stratification |
| Akkermansia | Paradoxically higher in AD | Previously observed in neurodegenerative cohorts |
Key implications
This work demonstrates that the AD gut microbiome is not a single disease-associated signature but a structured microbial landscape dominated by reproducible Prevotella- and Bacteroides-based ecotypes. The identification of a Bact2-like inflammatory enterotype in AD suggests a mechanistic link between microbial dysbiosis and neuroinflammatory progression. These findings emphasize that precision nutrition and microbiome-targeted interventions must account for underlying microbiota stratification to avoid one-size-fits-all approaches. Moreover, specific taxa—particularly Prevotella, Bacteroides, Faecalibacterium, and Escherichia/Shigella—represent promising microbial candidates for inclusion in microbiome signature databases aimed at clinical translation.
Citation
Yıldırım S, Nalbantoglu OU, Bayraktar A, et al. Stratification of the gut microbiota composition landscape across the Alzheimer’s disease continuum in a Turkish cohort.mSystems. 2022;7(1):e00004-22
Short-chain fatty acids are microbially derived metabolites that regulate epithelial integrity, immune signaling, and microbial ecology. Their production patterns and mechanistic roles provide essential functional markers within microbiome signatures and support the interpretation of MBTIs, MMAs, and systems-level microbial shifts across clinical conditions.